The evaluation of the gastrointestinal (GI) motility is useful to detect pathological conditions of the GI system, the therapeutic potential of drugs in motility disorders or potential drug side effects on motility or inflammation.
Current treatments are non-specific, focused on reducing motility or contractions of the GI tissues, often targeting the messengers (cyclic nucleotides cAMP and cGMP). Dr. Rehman’s group1 investigated one mechanism to regulate these messengers, specifically the phosphodiesterase (PDE) family of enzymes.
Targeting one PDE enzyme, Roflumilast, which has been shown to reduce inflammation in a cardio and renal context, Dr. Rehman’s team investigated GI applications, specifically antispasmodic effects on the small intestine. Using the emkaBATH4 to measure contractility, they show that spontaneous contractions are inhibited using Roflumilast similar to the known calcium blocker agent, Verapamil.